10-Q: Butterfly Network Reports Strong Revenue Growth and Reduced Losses in Q2 2025, Bolstered by Capital Raise

Butterfly Network, Inc. announced significant revenue increases and a narrower net loss for the second quarter and first half of 2025, supported by a successful $81 million public share offering.

Summary

• Total revenue increased by 8.8% to $23.383 million for the three months ended June 30, 2025, compared to $21.487 million in the prior year period.
• Product revenue grew by 13.5% to $16.621 million for the three months ended June 30, 2025, primarily driven by higher selling prices of the iQ3 probe and semiconductor chip deliveries.
• Software and other services revenue slightly decreased by 1.1% to $6.762 million for the three months ended June 30, 2025.
• Gross profit improved by 18.3% to $14.891 million for the three months ended June 30, 2025, with gross margin increasing to 63.7% from 58.6% in the prior year.
• Net loss for the three months ended June 30, 2025, narrowed to $13.834 million, an improvement from a net loss of $15.706 million in the same period last year.
• For the six months ended June 30, 2025, total revenue increased by 14.0% to $44.608 million, and net loss improved to $27.801 million from $37.467 million in the prior year period.
• Cash and cash equivalents significantly increased to $148.136 million as of June 30, 2025, up from $88.775 million at December 31, 2024.
• Net cash used in operating activities decreased by 38.6% to $18.844 million for the six months ended June 30, 2025, compared to $30.667 million in the prior year period.
• The company completed a public offering on January 31, 2025, issuing 27.6 million shares of Class A common stock and generating net proceeds of $81.0 million.

Sentiment

Score: 7

Explanation: While the company continues to operate at a loss, the significant improvements in revenue growth, gross margin, and reduction in net loss, coupled with a strong increase in cash reserves from a successful capital raise and improved operating cash flow, indicate positive momentum and a strengthened financial position. The decrease in units fulfilled and the slight dip in software revenue mix are minor concerns but are overshadowed by overall financial improvements and strategic cost reductions.

Positives

• Total revenue increased by 8.8% for the three months and 14.0% for the six months ended June 30, 2025, demonstrating strong top-line growth.
• Product revenue saw substantial growth of 13.5% for the quarter and 18.7% for the six-month period, driven by the higher selling price of the iQ3 probe and deliveries to an Octiv partner.
• Gross profit margin improved significantly to 63.7% for the quarter and 63.4% for the six-month period, reflecting higher average selling prices and manufacturing efficiencies.
• Net loss decreased by $1.872 million for the quarter and $9.666 million for the six-month period, indicating progress towards profitability.
• Net loss per common share improved to $(0.06) for the quarter and $(0.12) for the six-month period.
• Cash and cash equivalents increased by $59.361 million to $148.136 million as of June 30, 2025, strengthening the company's liquidity position.
• Net cash used in operating activities decreased by $11.823 million for the six months ended June 30, 2025, showing improved operational cash efficiency.
• Successfully raised $81.0 million in net proceeds from a public share offering, extending the cash runway.
• Reduced annual cash requirements by approximately $180 million since 2022, now less than $50 million annually.

Negatives

• Units fulfilled decreased by 5.1% for the three months ended June 30, 2025, primarily due to lower US probe sales volume after the iQ3's 2024 launch anniversary.
• Software and other services revenue slightly decreased by 1.1% for the three months ended June 30, 2025, and its mix as a percentage of total revenue decreased to 28.9% from 31.8%.
• Sales and marketing expenses increased by 18.8% for the quarter and 15.3% for the six-month period due to investments in sales force and marketing functions.
• Other operating expenses increased significantly by 227.9% for the quarter and 37.0% for the six-month period, driven by higher legal costs from litigation and employment-related costs not representative of ongoing operations.

Risks

• Growth is dependent on the ability to attract and retain customers.
• Business operations could be harmed if growth is not managed effectively.
• Current expectations and assumptions are subject to inherent risks, estimates, and uncertainties.
• The business is subject to various U.S. and foreign laws and regulations, which are subject to change and could adversely affect operations.
• Uncertainties exist regarding the pricing of products and services, and reimbursement for medical procedures conducted using the products.
• The ability to protect or enforce intellectual property rights is crucial for business success.
• Maintaining the listing of Class A common stock on the New York Stock Exchange is a continuous requirement.
• Economic downturns and political and market conditions beyond the company's control, including the imposition of tariffs, could negatively impact the business.
• Ongoing legal proceedings, including a putative class action lawsuit and stockholder derivative actions, pose financial and reputational risks with uncertain outcomes and potential for significant costs.
• Reliance on third-party manufacturers for inventory exposes the company to supply chain risks.
• The company faces risks related to inventory excess and obsolescence.

Future Outlook

The company expects to continue investing in its business to grow revenue and anticipates an improvement in profitability and margin expansion over time as its revenue mix shifts increasingly towards software and other services. It plans to invest additional resources to expand and further develop its SaaS and other service offerings. The company also expects a higher proportion of sales in healthcare systems compared to eCommerce as it expands healthcare system software offerings and develops relationships with larger healthcare systems. Existing cash and cash flows from operations are projected to be sufficient to meet liquidity, capital expenditure, and anticipated working capital requirements and fund operations for at least the next 12 months.

Management Comments

• "We expect to continue to invest in our business in order to grow revenue."
• "Since 2022, we have taken significant actions to reduce our cost of operations and extend our cash runway and have reduced our annual cash requirements by approximately $180 million, to less than $50 million annually."
• "Although we believe that our plans, intentions, and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions, or expectations."

Industry Context

Butterfly Network operates in the digital health sector, focusing on transforming medical imaging through portable, semiconductor-based ultrasound technology. Its proprietary 'Ultrasound-on-Chip' enables whole-body imaging with a single handheld probe, making ultrasound more accessible outside traditional healthcare institutions. The company's cloud-connected software integrates with clinical workflows and is accessible via mobile applications, tablets, and hospital systems, aiming to deliver imaging information at the point-of-care for earlier detection and remote health management. The company markets its solutions to healthcare systems, physicians, and providers, aligning with broader industry trends towards decentralized and accessible medical diagnostics.

Corporate Governance

Legal Proceedings

• Rose v. Butterfly Network, Inc., et al.: A putative class action lawsuit filed on February 16, 2022, alleging false and misleading statements and/or omissions about post-Business Combination business and financial prospects. The alleged class consists of persons who purchased or acquired the company's stock between January 12, 2021, and November 15, 2021, or exchanged Longview shares for the company's common stock. The lawsuit seeks unspecified damages, interest, and litigation costs. The company intends to vigorously defend against this action, but the outcome is uncertain, and a reasonable estimate of loss cannot be made.
• Koenig v. Todd M. Fruchterman, et al.: A stockholder derivative action filed on June 21, 2022, against the company's board of directors and the company as nominal defendant. Allegations include violation of Section 14(a) of the Exchange Act, breach of fiduciary duty, contribution, indemnification, aiding and abetting, and gross mismanagement, premised on allegedly inadequate internal controls and misleading representations regarding financial condition and earnings. The lawsuit seeks unspecified damages, disgorgement, restitution, interest, and litigation costs. The company intends to vigorously defend against this action, but the outcome is uncertain, and a reasonable estimate of loss cannot be made.
• Bhavsar v. Todd M. Fruchterman, et al.: A stockholder derivative action filed on November 28, 2023, with similar allegations to the Koenig action. The company intends to vigorously defend against this action, but the outcome is uncertain, and a reasonable estimate of loss cannot be made.

Stakeholder Impact

• Shareholders: Benefited from a successful capital raise that strengthened the company's cash position. Experienced improved financial performance with increased revenue and reduced net losses. Face potential dilution from the recent share offering and ongoing risks from litigation.
• Employees: Impacted by a 2024 business transformation initiative that led to reductions in force and optimized non-specialized technical functions, resulting in reduced personnel costs in R&D and G&A. Sales and marketing functions saw increased personnel costs due to investments. Employees participate in an Executive Severance Plan and an Employee Stock Purchase Plan.
• Customers: Benefit from continued product development, including the successful iQ3 probe, expanded software offerings, and the company's strategic focus on making medical imaging more accessible and integrated into clinical workflows.
• Suppliers/Vendors: The company maintains ongoing inventory purchase commitments with third-party manufacturers, indicating continued business relationships.
• Creditors: The company's improved cash position and reduced net cash used in operating activities could be viewed positively by creditors, indicating a stronger financial footing.

Next Steps

• Continue to invest in product and software development, clinical, and regulatory capabilities.
• Expand healthcare system software offerings and develop relationships with larger healthcare systems.
• Focus on operational efficiencies in the supply chain.
• Review the Executive Severance Plan at least annually.
• Evaluate the impact of new accounting pronouncements (ASU 2023-09 and ASU 2024-03) on financial statements and disclosures.

Key Dates

Recommendation

While Butterfly Network, Inc. shows promising improvements in revenue growth, gross margins, and a substantial reduction in net loss, alongside a strengthened cash position from a recent capital raise, it continues to operate at a loss. The decrease in units fulfilled and the slight dip in software revenue mix (which is expected to be more profitable long-term) present areas for continued monitoring. The ongoing legal proceedings also introduce an element of uncertainty. The company's strategic direction towards healthcare systems and continued investment in R&D are positive, but the path to sustained profitability is still unfolding. Therefore, a 'Hold' recommendation is appropriate, suggesting investors maintain their current position while observing future progress and risk mitigation.

Keywords

Ultrasound, Digital Health, Medical Imaging, Point-of-Care Ultrasound, Semiconductor Technology, SaaS, Healthcare Technology, Medical Devices, Diagnostic Imaging, Portable Ultrasound, SEC Filing, 10-Q